Missling did have some numbers in his backhand, otherwise he would not be able to say that both measures of the primary outcome were stat sig in both the 30mg and 50mg cohorts. Nor would he have been able to talk about the result of the SIMGAR1 WT. vs. variant genetic subgroups.
Anavex have more analysis to do before full presentation, but appear confident the data is worth a presentation at a scientific meeting.
Although unusual to PR trial results naked of any figures, pretty exciting and intriguing. Seems to be the Missling modus operandi.
News 
Market Data 
Discover 
